After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

The Rubik’s Cube has been reinvented with more games and many more screens for much more money. What has long been cherished as a simple toy yet complex puzzle requiring nothing but a healthy amount ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Siul Ruiz receives funding from The Royal Society. James Le Houx does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

Now in its eighth season, Ice Cube’s dream of the Big 3 has been realized several times over. Its mission seems to have adjusted over time, but he’s found ways to keep things going. For that, I think ...

Beneath the forest floor lies an overlooked secret: many plants grow a second set of roots far deeper than expected sometimes over three feet down tapping into hidden nutrient stores and potentially ...

For decades, Americans worried about their kids getting high. Now, alarming new data suggest they should be just as worried about their parents and grandparents—and demanding that their legislators ...

Experience the incredible as we build a house under the roots of a massive tree using only bamboo! This unique and innovative project showcases the beauty of working with natural materials to create a ...

June 10 (Reuters) - Recursion Pharmaceuticals (RXRX.O), opens new tab said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...